Profile picture

Professor Wolfgang Koenig

TUM Universitätsklinikum, German Heart Center, Munich (Germany)
Membership: FESC Member
Follow
Biography
Wolfgang Koenig, MD, FRCP, FACC, FAHA, FESC is a Professor of Cardiology. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Registry, he has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, where he is the Head of the Cardiometabolic Unit. Professor Koenig serves on the steering committee of multiple large clinical trials. His research also includes the molecular basis of atherothrombogenesis, and focuses on the identification and evaluation of new biomarkers for cardiometabolic diseases. He has published more than 900 papers in peer-reviewed journals. Between 2008–2017, he ranked sixtieth among the most frequently cited German speaking researchers in cardiovascular disease and has an H-Index of 101. He is a member of the Editorial Board of “Clinical Chemistry”. In 2020 he received the Paul-Morawitz-Award from the German Cardiac Society.
Logo ESC

Contributor content

Imaging or biomarkers: which is superior in risk prediction?
Session
Imaging or biomarkers: which is superior in risk prediction?
26 August 2023
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
Session
How to deal with residual cardiovascular risk in atherosclerotic disease? New pharmacotherapeutic options
29 August 2022
Prevention of cardiovascular diseases in the post-COVID19 era
Session
Prevention of cardiovascular diseases in the post-COVID19 era
28 August 2022
Cardiac biomarkers for atherosclerotic cardiovascular disease risk prediction
Session
Cardiac biomarkers for atherosclerotic cardiovascular disease risk prediction
30 August 2021
Emerging role of cardiac biomarkers in cardiovascular risk stratification
Session
Emerging role of cardiac biomarkers in cardiovascular risk stratification
17 April 2021
Non-troponin biomarkers in acute coronary syndromes
Session
Non-troponin biomarkers in acute coronary syndromes
1 September 2019
Emerging evidence-based approaches to reduce residual atherosclerotic risk
Session
Emerging evidence-based approaches to reduce residual atherosclerotic risk
25 August 2018
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)
Session
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)
26 August 2017
PCSK9i: translating LDL-C lowering into plaque regression and CV event reduction?
Session
PCSK9i: translating LDL-C lowering into plaque regression and CV event reduction?
30 August 2016
The relevance of biomarkers: a never ending story
Session
The relevance of biomarkers: a never ending story
28 August 2016

ESC 365 is supported by